Telesis Bio, Inc. (NASDAQ:TBIO – Get Free Report) shares fell 9.5% during mid-day trading on Wednesday . The stock traded as low as $0.38 and last traded at $0.38. 3,856 shares traded hands during trading, a decline of 99% from the average session volume of 410,007 shares. The stock had previously closed at $0.42.
Telesis Bio Price Performance
The firm has a 50-day moving average of $0.97 and a 200 day moving average of $2.59. The stock has a market capitalization of $785,880.00, a price-to-earnings ratio of -0.02 and a beta of 1.59.
Telesis Bio (NASDAQ:TBIO – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($3.83) earnings per share for the quarter. Telesis Bio had a negative net margin of 336.59% and a negative return on equity of 359.32%. The firm had revenue of $1.57 million during the quarter.
Telesis Bio Company Profile
Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.
Further Reading
- Five stocks we like better than Telesis Bio
- Transportation Stocks Investing
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- The How And Why of Investing in Oil Stocks
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.